AR050253A1 - Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento - Google Patents
Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamentoInfo
- Publication number
- AR050253A1 AR050253A1 ARP050102576A ARP050102576A AR050253A1 AR 050253 A1 AR050253 A1 AR 050253A1 AR P050102576 A ARP050102576 A AR P050102576A AR P050102576 A ARP050102576 A AR P050102576A AR 050253 A1 AR050253 A1 AR 050253A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- group
- cycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Compuesto derivado de indazol carboxamida que tienen la formula (1) en la cual Z es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido, estando dichos arilo y heteroarilo opcionalmente sustituidos con uno o más sustituyentes seleccionados, de manera independiente, del grupo consistente en : halo, alquilo C1-6 opcionalmente sustituido, haloalquilo C1-6 opcionalmente sustituido, heterocicloalquilo opcionalmetne sustituido, CN, N(Rb)SO2Re, N(Rb)C(O)Ra, C(O)NRaRb, C(O)NRaRb, C(O)NRxRy, SO2NRaRb, SO2NRxRy, ORc, N(Rb)C(O)NRaRb, N(Rb)C(0)NRxRy, N(Rb)C(O)ORd, estando dichos alquilo C1-6 y haloalquilo C1-6 opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo consistente en: NRaRb, cicloalquilo C3-6, ORc, fenilo y heterocicloalquilo opcionalmente sustituido con uno o dos grupos alquilo C1-6; R1 es H, halo, o -WX; W es un enlace o alquileno C1-6; X es arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, cicloalquilo C4-7 opcionalmente sustituido, cicloalquenilo C5-7 opcionalmente sustituido, N(Rb)SO2Re, N(Rb) C(O)Re, N(Rb)C(O)ORd, N(Rb)C(O)NRaRb, o N(Rb)C(o)NRxRy, estando dichos arilo, heteroarilo, heterocicloalquilo, cicloalquilo C4-7, y cicloalquenilo C5-7 opcionalmente sustituidos con uno o más sustituyentes seleccionados de manera independiente del grupo consistente en: halo, alquilo C1-6 opcionalmente sustituido, haloalquilo C1-6 opcionalmente sustituido, ORc, C(O)Rg, C(O)ORf, N(Rb)SO2Re, N(Rb)C(O)Ra, C(O)NRaRb, SO2NRaRb, SO2Re, y heterocicloalquilo, estando dichos alquilo C1-6 y haloalquilo C1-6 opcionalmente sustituidos con un grupo fenilo; cada Ra está seleccionado, de manera independiente, del grupo consistente en H, alquilo, C1-3 opcionalmente sustituido, fenilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo C3-7 opcionalmente sustituido, y heterocicloalquilo opcionalemtne sustituido, estando dicho alquilo C1-3 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: halo, ORc, haloalquilo C1-6, fenilo y heteroarilo; y estando dichos fenilo, heteroarilo, cicloalquilo C3-7, y heterocicloalquilo opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo consistente en: halo, ORc, alquilo C1-6, y haloalquilo C1-6 cada Rb está seleccionado, de manera indendiente, del grupo consiste en: H y alquilo C1-3 opcionalemente sustituido, estando dicho alquilo C1-3 opcionalmente sustituido con uno o más grupos ORc; cada Rc está seleccionado, de manera independiente, del grupo consistente en: H, alquilo C1-6 opcionalmente sustituido, cicloalquilo C3-7 opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, y arilo opcionalmente sustituido, y arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, estando dichos alquilo C1-6 y haloalquilo C1-6 opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo consistente en: cicloalquilo C3-6, fenilo, heterocicloalquilo, y heteroarilo; y estando dichos arilo y heteroarilo opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo consistente en: halo, alquilo C1-3, haloalquilo C1-3 y OH; y estando dichos cicloalquilo C3-7 y heterocicloalquilo opcionalmente sustituidos con uno o más grupos alquilo C1-3; cara Rd es alquilo C1-3 opcionalmente sustituido de manera independiente, estando dicho alquilo C1-3 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: cicloalquilo C3-6, fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: halo, alquilo C1-6, y cicloalquilo C3-6; y heteroarilo opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: halo, alquilo C1-6, y cicloalquilo C3-6; cada Re está seleccionado, de manera independiente, del grupo consistente en: alquilo C1-6 opcionalmente sustituido, fenilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo C5-7 opcionalmente sustituido, y heterocicloalquilo opcionalmente sustituido, estando dicho alquilo C1-6 opcionalmente sustituido con un sustituyente seleccionado del grupo consistente en: ORc, trifluorometilo, fenilo, heteroarilo, heterocicloalquilo opcionalmente sustituido con ORc o con heterocicloalquilo, NRaRb; estando dichos fenilo y heteroarilo opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: halo, CN, alquilo C1-6, N(Rb)C(O)Ra, y ORh; y estando dichos cicloalquilo C5-7 y heterocicloalquilo opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo consistente en: halo, alquilo C1-6 opcionalmente sustituido con ORc, y cicloalquilo C3-6, cada Rf está seleccionado, de manera independiente, del grupo consistente en H y alquilo C1-4 opcionalmente sustituido, pudiendo estar dicho alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: cicloalquilo C3-6; fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: halo, alquilo C1-6, y heteroarilo opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: halo, alquilo C1-6, y cicloalquilo C3-6; cada Rg está seleccionado, de manera independiente, del grupo consistente en: alquilo C1-3 opcionalmente sustituido, fenilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo C3-7 opcionalmente sustituido y heterocicloalquilo opcionalmente sustituido, estando dicho alquilo C1-3 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en: halo y haloalquilo C1-6; y estando dichos fenilo, heteroarilo, cicloalquilo C3-7, y heterocicloalquilo opcionalmente sustituidos con uno o más fenilo, heteroarilo, cicloalquilo C3-7, y heterocicloalquilo opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo consistente en: Halo, alquilo C1-6, y halolaquilo C1-6, cada Rh está seleccionado, de manera independiente, del grupo consistente en: H, alquilo C1-6, y haloalquilo C1-6; y Rx y Ry, tomados junto con el átomo de nitrogeno al cual están unidos, forman un anillo que tiene de 5 a 7 átomos miembros, conteniendo opcionalmente dicho anillo un heteroátomo adicional como átomo miembro siendo dicho anillo saturado o insaturado, pero no aromático, y estando dicho anillo opcionalmente sustituido con uno o dos sustituyentes alquilo C1-3; o una de sus sales faramcéuticamente aceptables. Composicion que lo comprende y su uso para la preparacion de un medicamento para tratar trastornos en los que interviene una actividad inadecuada de IKK2 ( denominado también IKKbeta), tales como la artritis reumatoide, el asma y la enfermedad pulmonar obstructiva cronica (EPOC, siglas inglesas COPD), transtornos inflamatorios, enfermedad de Alzheimer, SIDA, infarto, cáncer o caquexia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58265504P | 2004-06-24 | 2004-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050253A1 true AR050253A1 (es) | 2006-10-11 |
Family
ID=35782386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102576A AR050253A1 (es) | 2004-06-24 | 2005-06-22 | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
Country Status (21)
Country | Link |
---|---|
US (1) | US8501780B2 (es) |
EP (1) | EP1758578B1 (es) |
JP (1) | JP5017105B2 (es) |
KR (1) | KR20070043940A (es) |
CN (1) | CN101005836A (es) |
AR (1) | AR050253A1 (es) |
AT (1) | ATE493396T1 (es) |
AU (1) | AU2005258332A1 (es) |
BR (1) | BRPI0512533A (es) |
CA (1) | CA2571712A1 (es) |
DE (1) | DE602005025632D1 (es) |
ES (1) | ES2358579T3 (es) |
IL (1) | IL179747A0 (es) |
MA (1) | MA28727B1 (es) |
MX (1) | MXPA06014481A (es) |
NO (1) | NO20070076L (es) |
PE (1) | PE20060373A1 (es) |
RU (1) | RU2007102576A (es) |
TW (1) | TW200616967A (es) |
WO (1) | WO2006002434A2 (es) |
ZA (1) | ZA200609759B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
PE20060748A1 (es) * | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
WO2007005534A2 (en) * | 2005-06-30 | 2007-01-11 | Smithkline Beecham Corporation | Chemical compounds |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
JP2009516702A (ja) * | 2005-11-18 | 2009-04-23 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
EP1986643A1 (en) * | 2006-02-10 | 2008-11-05 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
JP5019768B2 (ja) * | 2006-03-23 | 2012-09-05 | 独立行政法人科学技術振興機構 | 新規低分子化合物およびその製造方法 |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
GB0715087D0 (en) * | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
GB0804591D0 (en) * | 2008-03-12 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
GB0804592D0 (en) * | 2008-03-12 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
US8299055B2 (en) | 2008-10-02 | 2012-10-30 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and the use thereof |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
WO2010120854A1 (en) * | 2009-04-15 | 2010-10-21 | Glaxosmithkline Llc | Chemical compounds |
JP2015214492A (ja) * | 2012-09-07 | 2015-12-03 | 大日本住友製薬株式会社 | 3−(4−ピペリジル)−インダゾール誘導体 |
UY37412A (es) | 2016-09-23 | 2018-04-30 | Novartis Ag | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos |
JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
AU2020304036A1 (en) * | 2019-06-27 | 2022-01-06 | Biogen Ma Inc. | 2H-indazole Derivatives and their use in the treatment of disease |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775761A (en) * | 1983-08-22 | 1988-10-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles |
US5256673A (en) * | 1983-11-25 | 1993-10-26 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds |
DE3342632A1 (de) | 1983-11-25 | 1985-06-05 | Merck Patent Gmbh, 6100 Darmstadt | Indolderivate |
ES2059408T3 (es) | 1987-02-10 | 1994-11-16 | Abbott Lab | Un proceso para la preparacion de un compuesto. |
JPH0262875A (ja) * | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
IE903206A1 (en) | 1989-09-07 | 1991-03-13 | Abbott Lab | Indole-, benzofuran-, and benzothiophene-containing¹lipoxygenase-inhibiting compounds |
US5254473A (en) * | 1990-03-16 | 1993-10-19 | Jp Laboratories | Solid state device for monitoring integral values of time and temperature of storage of perishables |
JP2963288B2 (ja) | 1992-01-14 | 1999-10-18 | 株式会社海洋バイオテクノロジー研究所 | 水中有害付着生物防除剤 |
US5330986A (en) * | 1992-11-24 | 1994-07-19 | Hoechst-Roussel Pharmaceuticals Inc. | Indole-7-carboxamide derivatives |
FR2701026B1 (fr) | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
GB9305623D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
AU6215594A (en) | 1993-03-18 | 1994-10-11 | Merck Sharp & Dohme Limited | Indole derivatives as dopamine d4 antagonists |
ZA951822B (en) * | 1994-12-23 | 1996-09-26 | Glaxo Group Ltd | Chemical compounds |
DE19500689A1 (de) | 1995-01-12 | 1996-07-18 | Merck Patent Gmbh | Indolpiperidin-Derivate |
EP0831809A4 (en) | 1995-06-07 | 2001-11-28 | Sugen Inc | METHODS AND COMPOUNDS FOR INHIBITING ADAPTIVE PROTEIN / TYROSINE KINASE INTERACTIONS |
GB9610811D0 (en) | 1996-05-23 | 1996-07-31 | Pharmacia Spa | Combinatorial solid phase synthesis of a library of indole derivatives |
US5846982A (en) | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
EP1077213A3 (en) | 1996-06-14 | 2001-06-13 | Eli Lilly And Company | Inhibition of serotonin reuptake |
JP2001506230A (ja) | 1996-08-09 | 2001-05-15 | スミスクライン・ビーチャム・コーポレイション | 新規ピペラジン含有化合物 |
IL134301A0 (en) | 1997-08-06 | 2001-04-30 | Lilly Co Eli | 2-acylaminopropanamines as tachykinin receptor antagonists |
AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
DE19756036A1 (de) * | 1997-12-17 | 1999-06-24 | Merck Patent Gmbh | Amid- und Harnstoffderivate |
JP2002515891A (ja) | 1997-12-19 | 2002-05-28 | スミスクライン・ビーチャム・コーポレイション | 新規なピペリジン含有化合物 |
DE19807993A1 (de) | 1998-02-26 | 1999-09-02 | Bayer Ag | Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten |
ATE264841T1 (de) | 1998-02-27 | 2004-05-15 | Kissei Pharmaceutical | Indol-derivate und medizinische zusammensetzungen die diese enthalten |
US6589954B1 (en) * | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
JP2002519348A (ja) | 1998-06-30 | 2002-07-02 | イーライ・リリー・アンド・カンパニー | 5−ht1fアゴニスト |
DE19928424A1 (de) | 1999-06-23 | 2000-12-28 | Aventis Pharma Gmbh | Substituierte Benzimidazole |
ATE301651T1 (de) | 1999-06-23 | 2005-08-15 | Aventis Pharma Gmbh | Substituierte benzimidazole |
MXPA02001568A (es) * | 1999-08-13 | 2002-07-02 | Vela Pharmaceuticals Inc | Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma. |
DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
US6245799B1 (en) * | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
EP1228065A1 (en) | 1999-11-08 | 2002-08-07 | Wyeth | (indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
EP1134221A1 (en) | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
WO2001068648A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
EP1209158A1 (en) | 2000-11-18 | 2002-05-29 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines |
CA2407370A1 (en) * | 2000-04-24 | 2001-11-01 | Bristol-Myers Squibb Company | Heterocycles that are inhibitors of impdh enzyme |
US6627645B2 (en) | 2000-04-28 | 2003-09-30 | Acadia Pharmaceuticals, Inc. | Muscarinic agonists |
AU2001256714A1 (en) | 2000-05-15 | 2001-11-26 | Kissei Pharmaceutical Co. Ltd. | Water-based liquid preparation |
US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
WO2002014317A2 (en) | 2000-08-14 | 2002-02-21 | Ortho Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
US20030171413A1 (en) | 2000-08-17 | 2003-09-11 | Owen David Alan | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders |
US6868504B1 (en) * | 2000-08-31 | 2005-03-15 | Micron Technology, Inc. | Interleaved delay line for phase locked and delay locked loops |
MXPA03001960A (es) * | 2000-09-06 | 2004-03-18 | Johnson & Johnson | Un metodo para tratar alergias. |
JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
US6869956B2 (en) * | 2000-10-03 | 2005-03-22 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) |
ES2260300T3 (es) | 2000-10-03 | 2006-11-01 | Bristol-Myers Squibb Company | Compuestos tetraciclicos sustituidos con amino utiles como agentes antiinflamatorios y composiciones farmaceuticas que comprenden los mismos. |
WO2002030353A2 (en) | 2000-10-12 | 2002-04-18 | Smithkline Beecham Corporation | NF-λB INHIBITORS |
WO2002030423A1 (en) | 2000-10-12 | 2002-04-18 | Smithkline Beecham Corporation | NF-λB INHIBITORS |
ES2305125T3 (es) | 2000-10-26 | 2008-11-01 | Amgen Inc. | Agentes anti-inflamatorios. |
JP2002193938A (ja) | 2000-12-01 | 2002-07-10 | Bayer Ag | 4−アリールピリジン誘導体 |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
JP4307073B2 (ja) | 2000-12-22 | 2009-08-05 | ワイス | 5−ヒドロキシトリプトアミン−6リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物 |
CZ20032287A3 (cs) | 2001-02-01 | 2004-02-18 | Bristol-Myers Squibb Company | Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK) |
DE10112151A1 (de) | 2001-03-14 | 2002-09-19 | Merck Patent Gmbh | Substituierte Benzofuran-2-carbonsäureamide |
WO2002094265A1 (en) | 2001-05-24 | 2002-11-28 | Leo Pharma A/S | A method of modulating nf-$g(k)b activity |
US20030045515A1 (en) | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
CA2447021C (en) | 2001-05-24 | 2010-08-10 | Leo Pharma A/S | Pyridyl cyanoguanidine compounds |
JP4187642B2 (ja) * | 2001-06-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を有する新規インドール誘導体 |
US6638679B2 (en) | 2001-07-12 | 2003-10-28 | Kodak Polychrome Graphics, Llc | Photosensitive compositions having mixtures of alkoxy and non-alkoxy diazonium salt containing compounds |
SE0102617D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
US20030127204A1 (en) | 2001-09-06 | 2003-07-10 | Varnell Daniel F. | Amphoteric polymer resins that increase the rate of sizing development |
US6849653B2 (en) | 2001-09-19 | 2005-02-01 | Pharmacia Corporation | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
US20030109550A1 (en) * | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
CA2460939C (en) | 2001-09-19 | 2008-07-29 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
WO2003024935A2 (en) | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
EP1444010A2 (en) | 2001-10-30 | 2004-08-11 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
PT1476136E (pt) | 2002-02-14 | 2006-10-31 | Glaxo Group Ltd | Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco. |
EP1490371B1 (en) | 2002-04-03 | 2007-08-15 | Bristol-Myers Squibb Company | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same |
WO2003087087A2 (en) | 2002-04-09 | 2003-10-23 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
AR039280A1 (es) * | 2002-04-11 | 2005-02-16 | Smithkline Beecham Corp | Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica |
MXPA04010952A (es) | 2002-05-09 | 2005-01-25 | Pharmacia Corp | Compuestos de pirazolilo sustituidos para el tratamiento de la inflamacion. |
US20040034084A1 (en) * | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
AU2003227522A1 (en) | 2002-05-30 | 2003-12-19 | Neurosearch A/S | 3-substituted quinuclidines and their use |
US7375131B2 (en) | 2002-06-06 | 2008-05-20 | Smithklinebeecham Corp. | NF-κB inhibitors |
EP1513516B1 (en) | 2002-06-06 | 2008-12-03 | Boehringer Ingelheim Pharmaceuticals Inc. | SUBSTITUTED 3-AMINO-THIENO(2,3-b) PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES |
DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
BR0313923A (pt) | 2002-08-29 | 2005-07-12 | Boehringer Ingelheim Pharma | Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas |
US6919334B2 (en) | 2002-09-12 | 2005-07-19 | Wyeth | Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine |
US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
US6911445B2 (en) | 2002-09-12 | 2005-06-28 | Wyeth | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
KR20050085115A (ko) | 2002-11-22 | 2005-08-29 | 스미스클라인 비참 코포레이션 | 신규 화합물 |
BR0316950A (pt) * | 2002-12-02 | 2006-01-17 | Hoffmann La Roche | Derivados de indazol como antagonistas de crf |
US20060116419A1 (en) * | 2002-12-06 | 2006-06-01 | Callahan James F | Nf-kb inhibitors |
DE10259244A1 (de) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
US7329668B2 (en) | 2003-02-25 | 2008-02-12 | Bristol-Myers Squibb Company | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
EP1651629A1 (en) | 2003-07-31 | 2006-05-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzothiophene compounds and uses thereof |
BRPI0415390A (pt) | 2003-10-14 | 2006-12-12 | Pharmacia Corp | compostos de pirazinona substituìda para o tratamento da inflamação |
EP1692128A1 (en) * | 2003-11-19 | 2006-08-23 | Signal Pharmaceuticals LLC | Indazole compounds and methods of use thereof as protein kinase inhibitors |
EP1694686A1 (en) * | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
GB0400895D0 (en) | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
DE102004012069A1 (de) * | 2004-03-12 | 2005-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel |
TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
PE20060748A1 (es) * | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
EP1869052A1 (en) | 2005-04-06 | 2007-12-26 | AstraZeneca AB | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
CN101247853B (zh) | 2005-04-13 | 2014-11-12 | 轴突公司 | 具有nos抑制活性的取代的吲哚化合物 |
US8063071B2 (en) * | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
WO2007010964A1 (ja) | 2005-07-22 | 2007-01-25 | Shionogi & Co., Ltd. | Pgd2受容体アンタゴニスト活性を有するインドール誘導体 |
US20080242685A1 (en) * | 2005-10-25 | 2008-10-02 | Smithkline Beecham Corporation | Chemical Compounds |
JP2009513677A (ja) * | 2005-10-25 | 2009-04-02 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
JP2009516702A (ja) * | 2005-11-18 | 2009-04-23 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
JP2009519968A (ja) * | 2005-12-16 | 2009-05-21 | スミスクライン・ビーチャム・コーポレイション | 化学物質 |
JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
TW200836724A (en) * | 2006-09-22 | 2008-09-16 | Glaxo Group Ltd | Novel compounds |
AR065804A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
GB0710528D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
GB0804592D0 (en) | 2008-03-12 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
-
2005
- 2005-06-22 TW TW094120713A patent/TW200616967A/zh unknown
- 2005-06-22 PE PE2005000715A patent/PE20060373A1/es not_active Application Discontinuation
- 2005-06-22 AR ARP050102576A patent/AR050253A1/es unknown
- 2005-06-24 MX MXPA06014481A patent/MXPA06014481A/es unknown
- 2005-06-24 AT AT05769167T patent/ATE493396T1/de not_active IP Right Cessation
- 2005-06-24 DE DE602005025632T patent/DE602005025632D1/de active Active
- 2005-06-24 AU AU2005258332A patent/AU2005258332A1/en not_active Abandoned
- 2005-06-24 WO PCT/US2005/022870 patent/WO2006002434A2/en active Application Filing
- 2005-06-24 CN CNA200580028413XA patent/CN101005836A/zh active Pending
- 2005-06-24 KR KR1020067027143A patent/KR20070043940A/ko not_active Application Discontinuation
- 2005-06-24 BR BRPI0512533-2A patent/BRPI0512533A/pt not_active IP Right Cessation
- 2005-06-24 RU RU2007102576/04A patent/RU2007102576A/ru not_active Application Discontinuation
- 2005-06-24 ES ES05769167T patent/ES2358579T3/es active Active
- 2005-06-24 CA CA002571712A patent/CA2571712A1/en not_active Abandoned
- 2005-06-24 EP EP05769167A patent/EP1758578B1/en active Active
- 2005-06-24 JP JP2007518364A patent/JP5017105B2/ja not_active Expired - Fee Related
- 2005-06-24 US US11/570,060 patent/US8501780B2/en not_active Expired - Fee Related
-
2006
- 2006-11-23 ZA ZA200609759A patent/ZA200609759B/en unknown
- 2006-11-30 IL IL179747A patent/IL179747A0/en unknown
- 2006-12-29 MA MA29580A patent/MA28727B1/fr unknown
-
2007
- 2007-01-05 NO NO20070076A patent/NO20070076L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US8501780B2 (en) | 2013-08-06 |
DE602005025632D1 (de) | 2011-02-10 |
BRPI0512533A (pt) | 2008-03-25 |
ATE493396T1 (de) | 2011-01-15 |
AU2005258332A1 (en) | 2006-01-05 |
NO20070076L (no) | 2007-02-26 |
IL179747A0 (en) | 2007-05-15 |
RU2007102576A (ru) | 2008-07-27 |
EP1758578A4 (en) | 2009-05-27 |
EP1758578A2 (en) | 2007-03-07 |
ES2358579T3 (es) | 2011-05-11 |
CN101005836A (zh) | 2007-07-25 |
MXPA06014481A (es) | 2007-03-01 |
US20070281933A1 (en) | 2007-12-06 |
WO2006002434A2 (en) | 2006-01-05 |
CA2571712A1 (en) | 2006-01-05 |
EP1758578B1 (en) | 2010-12-29 |
MA28727B1 (fr) | 2007-07-02 |
JP5017105B2 (ja) | 2012-09-05 |
ZA200609759B (en) | 2007-10-31 |
TW200616967A (en) | 2006-06-01 |
WO2006002434A3 (en) | 2006-06-15 |
KR20070043940A (ko) | 2007-04-26 |
PE20060373A1 (es) | 2006-04-29 |
JP2008504296A (ja) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050253A1 (es) | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento | |
PH12019501786A1 (en) | Hiv inhibitor compound | |
CY1119771T1 (el) | Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak | |
MD20150019A2 (ro) | Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubile | |
AR108326A1 (es) | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas | |
AR065804A1 (es) | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento | |
EA201291273A1 (ru) | Ингибиторы киназ, регулирующих апоптозный сигнал | |
AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
JP2014508753A5 (es) | ||
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
AR110782A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
MA35804B1 (fr) | Modulation de l'expression du virus de l'hepatite b (vhb) | |
JP2016534148A5 (es) | ||
CL2014000122A1 (es) | Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades. | |
MX2021010242A (es) | Compuesto inhibidor de jak y uso del mismo. | |
EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
JP2013010793A5 (es) | ||
EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
JP2017502092A5 (es) | ||
EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
EA201391018A1 (ru) | Препараты иммуносупрессантов | |
WO2018171688A1 (en) | Atf3 induction compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |